Selected article for: "hazard ratio and increase risk"
Author: Khawaja, Fareed; Chemaly, Roy F.
Title: Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies
  • Document date: 2019_7_23
    • ID: 4fx18mlj_8
    Snippet: In a cohort of 237 allogeneic HCT recipients with RSV infection, the hazard ratio (HR) of experiencing progression from RSV URTI to LRTI was 4.1 for an absolute neutrophil count of <500 cells/mL and 2.6 for an absolute lymphocyte count of <200 cells/mL, 53 making them the most predictive factors for progression. 53 Among leukemia patients, post-induction chemotherapy neutropenia and leukopenia have also been shown to increase the risk of progress.....
    Document: In a cohort of 237 allogeneic HCT recipients with RSV infection, the hazard ratio (HR) of experiencing progression from RSV URTI to LRTI was 4.1 for an absolute neutrophil count of <500 cells/mL and 2.6 for an absolute lymphocyte count of <200 cells/mL, 53 making them the most predictive factors for progression. 53 Among leukemia patients, post-induction chemotherapy neutropenia and leukopenia have also been shown to increase the risk of progression to LRTI. 22, 24 In a recent retrospective study, neutropenia and lymphopenia were not independently associated with progression of disease in HM patients, but the combination of the two factors was associated with a higher risk of progression. 37 However, time from last chemotherapy was not shown to play a role in progression to LRTI in HM patients. 37 On the other hand, lack of ribavirin therapy was associated with progression of dishaematologica | 2019; 104(7) 37, 53, 58 The protective benefits of ribavirin are discussed further in the treatment section.

    Search related documents:
    Co phrase search for related documents
    • absolute lymphocyte count and hazard ratio: 1, 2, 3, 4, 5
    • absolute lymphocyte count and HCT recipient: 1
    • absolute lymphocyte count and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • absolute lymphocyte count and HM patient: 1
    • absolute lymphocyte count and hr hazard ratio: 1, 2
    • allogeneic RSV infection HCT recipient and HCT recipient: 1
    • allogeneic RSV infection HCT recipient and LRTI progression: 1
    • chemotherapy time and disease progression: 1, 2, 3
    • chemotherapy time and hazard ratio: 1, 2, 3
    • chemotherapy time and high risk: 1, 2, 3, 4, 5
    • chemotherapy time and hr hazard ratio: 1
    • chemotherapy time and LRTI progression: 1
    • chemotherapy time and LRTI progression risk: 1
    • disease progression and hazard ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease progression and HCT recipient: 1
    • disease progression and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease progression and hr hazard ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease progression and leukemia patient: 1, 2
    • disease progression and LRTI progression: 1